Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.45 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 8/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675944 | 0.99 | RIPK1 (0.45) | RIPK1GSK3BGSK3AMAPK1HDAC6 | |
| SCHEMBL16675949 | 0.90 | GSK3B (0.46) | RIPK1GSK3BGSK3AMAPK1MAP2K4 | |
| SCHEMBL16675961 | 0.84 | RIPK1 (0.41) | RIPK1GSK3BGSK3AMAPK1 | |
| SCHEMBL16769268 | 0.82 | MAP2K4 (0.44) | RIPK1GSK3BMAPK1HDAC6MAP2K4 | |
| SCHEMBL16752817 | 0.82 | MAP2K4 (0.44) | RIPK1GSK3BGSK3AMAPK1HDAC6 | |
| SCHEMBL16752820 | 0.82 | MAP2K4 (0.44) | RIPK1GSK3BGSK3AMAPK1HDAC6 | |
| SCHEMBL16752823 | 0.82 | MAP2K4 (0.44) | RIPK1GSK3BGSK3AMAPK1HDAC6 | |
| SCHEMBL16769269 | 0.82 | MAP2K4 (0.44) | RIPK1GSK3BGSK3AMAPK1HDAC6 | |
| SCHEMBL16675964 | 0.81 | GSK3B (0.49) | GSK3BGSK3AHDAC6 | |
| SCHEMBL16675963 | 0.80 | GSK3B (0.48) | GSK3BGSK3AHDAC6MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | RIPK1 3768/4885GSK3B 4407/4885GSK3A 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.